This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Tecvayli (teclistamab-cqyv)
General Description:
Tecvayli (teclistamab-cqyv) is a bispecific T-cell–engaging antibody that targets both B-cell maturation antigen (BCMA) on multiple myeloma cells and CD3 on T-cells. It is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
By binding to BCMA and CD3, Tecvayli redirects T-cells to recognize and eliminate myeloma cells, providing a novel, immune-based treatment option for patients who have exhausted standard therapies.
Tecvayli was approved by the U.S. Food and Drug Administration (FDA) for this indication and has also been authorized by the European Medicines Agency (EMA), marking a significant advancement in multiple myeloma treatment.
Disease Indications:
Multiple Myeloma
Manufacturer:
Janssen Biotech, Inc.
Usage:
Subcutaneous
Medicine Approved by:
• European Medicines Agency (EMA)
• Food and Drug Administration (FDA)
Package:
• 30 mg/3 mL (10 mg/mL) single-dose vial
• 153 mg/1.7 mL (90 mg/mL) single-dose vial
Shipping:
Cold Chain Shipping
Certain biologic medicines, including Tecvayli, are sensitive to heat, light, and handling. To maintain the product’s stability and therapeutic integrity, Tecvayli is shipped under strict cold chain conditions using specialized medical couriers equipped with temperature-controlled packaging and vehicles.
While cold chain delivery may be slightly more expensive than standard shipping, it ensures the medicine’s quality and effectiveness upon arrival.
How to Access Tecvayli (teclistamab-cqyv) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Tecvayli (teclistamab-cqyv) is not yet approved or commercially available in India, MitoGENE can assist patients and healthcare providers in obtaining it legally through the Named Patient Program (NPP).
Here’s how the process works:
